CAMP4 Therapeutics, a clinical-stage biotech developing RNA-based therapies to target genetic diseases, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, CAMP4 Therapeutics would command a fully diluted market value of $280.2 million.
The company is developing regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. It is developing a proprietary RNA Actuating Platform to identify and characterize the active regulatory elements controlling expressed genes. Once a disease-associated target gene is identified, it plans to apply the platform to identify the controlling regRNA and rapidly generate novel antisense oligonucleotide, or ASO, candidates. CAMP4 Therapeutics is initially focused on metabolic and central nervous system, or CNS, diseases with validated disease biology, which it believes its platform can help address. Its lead candidate, meant to target urea cycle disorders, is undergoing a Phase 1 trial, which it expects reports from in 2025.
CAMP4 Therapeutics was founded in 2015 and plans to list on the Nasdaq under the symbol CAMP. J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair are the joint bookrunners on the deal. It is expected to price during the week of October 7, 2024.
